PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Conditions: Triple Negative Breast Cancer Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Pembrolizumab; Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Olaparib; Drug: Capecitabine Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Not yet recruiting

https://clinicaltrials.gov/study/NCT06245889

Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials